isoniazid has been researched along with Genetic Predisposition in 34 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis." | 9.17 | NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. ( Azuma, J; Fujio, Y; Kamimura, S; Kawase, I; Kubota, R; Nagai, T; Ohno, M; Okuda, Y; Takashima, T; Tsuyuguchi, K; Yokota, S, 2013) |
| "Genetic variants in NAT2 are associated with pharmacokinetic variation of isoniazid, the cornerstone of antituberculosis treatment." | 7.80 | Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. ( Aarnoutse, RE; Coenen, MJ; de Waard, JH; García, JF; Hermans, PW; López, D; Schijvenaars, MM; Verhagen, LM, 2014) |
| "This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis." | 5.17 | NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. ( Azuma, J; Fujio, Y; Kamimura, S; Kawase, I; Kubota, R; Nagai, T; Ohno, M; Okuda, Y; Takashima, T; Tsuyuguchi, K; Yokota, S, 2013) |
| "Isoniazid (INH) is part of the first-line-therapy for tuberculosis (TB) but can cause drug-induced liver injury (DILI)." | 3.85 | Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. ( Aminkeng, F; Brunham, LR; Chan, SL; Chee, CBE; Chua, APG; Gan, SH; Jin, S; Loh, M; Wang, YT, 2017) |
| "Isoniazid (INH) is the most effective drug used as a first-line tuberculosis (TB) treatment besides rifampicin, pyrazinamide, and ethambutol." | 3.83 | NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs. ( Bencheikh, RS; Bourkadi, JE; El Bouazzi, O; Guaoua, S; Hammi, S; Ratbi, I; Sefiani, A; Tebaa, A, 2016) |
| "Genetic variants in NAT2 are associated with pharmacokinetic variation of isoniazid, the cornerstone of antituberculosis treatment." | 3.80 | Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. ( Aarnoutse, RE; Coenen, MJ; de Waard, JH; García, JF; Hermans, PW; López, D; Schijvenaars, MM; Verhagen, LM, 2014) |
| "This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens." | 3.80 | N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. ( Ahmed, MU; Aithal, GP; Al Maruf, A; Daly, AK; Day, CP; Hasnat, A; Ng, CS; Pirmohamed, M, 2014) |
| "Antituberculosis drug-induced hepatitis attributed to isoniazide (INH) is one of the most prevalent drug-induced liver injuries." | 3.78 | Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. ( Ben Mahmoud, L; Ghozzi, H; Hachicha, H; Hakim, A; Hammami, S; Kamoun, A; Makni, H; Sahnoun, Z; Zalila, N; Zeghal, K, 2012) |
| "A case-control study including Caucasian patients with tuberculosis (TB) treated with isoniazid, rifampicin and pyrazinamide." | 3.77 | N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. ( Agúndez, JA; Botana-Rial, M; Constenla, L; Fernández-Villar, A; Leiro-Fernandez, V; Valverde, D; Vázquez-Gallardo, R, 2011) |
| "The activity of urinary N-acetylamino-transferase was determined by high-performance liquid chromatographic assay of acetylisoniazid and isoniazid after administration of isoniazid to healthy Japanese male and bladder cancer patients in Japan." | 3.69 | N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. ( Hanaoka, T; Hashida, C; Ishizu, S; Maeda, K; Ohishi, Y, 1995) |
| "However, how cancer patterns in humans compare to those of other species remains largely unknown." | 2.58 | From humans to hydra: patterns of cancer across the tree of life. ( Albuquerque, TAF; de Magalhães, JP; Doherty, A; Drummond do Val, L, 2018) |
| "hydrazine) can cause mitochondrial injury, which can lead to mitochondrial oxidant stress and impairment of energy homeostasis." | 2.50 | Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. ( Boelsterli, UA; Lee, KK, 2014) |
| " Moreover, the rs1495741 genotypes showed an association with the isoniazid dosage required for induction of hepatotoxicity." | 1.39 | The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. ( Ho, HT; Hsiong, CH; Hu, OY; Huang, TY; Jong, YJ; Lu, PL; Perng, WC; Wang, NC; Wang, TH, 2013) |
| "Large-scale screening for NAT2 and CYP2E1 genotypes can prove useful in predicting the risk of adverse effects." | 1.39 | N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. ( Callegari-Jacques, SM; de Carvalho, DC; Fernandes, DC; Hutz, MH; Ribeiro Dos Santos, AK; Santos, NP; Santos, SE; Silva, CA; Vallinoto, AC, 2013) |
| "Tuberculosis (TB) treatment can cause serious sequelae including adverse effects such as anti-TB drug-induced hepatotoxicity (ATDH)." | 1.38 | Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. ( Fukushima, K; Higuchi, N; Inamine, T; Kohno, S; Kondo, S; Mawatari, T; Nakaura, A; Nanashima, K; Suyama, N; Tahara, N; Tsukamoto, K; Yanagihara, K, 2012) |
| "Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic poses significant challenges for the diagnostic and treatment of both diseases." | 1.35 | Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. ( Bronson, RT; Kramnik, I; Nalbandian, A; Pichugin, A; Yan, BS, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 4 (11.76) | 29.6817 |
| 2010's | 26 (76.47) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, H | 1 |
| Wu, T | 1 |
| Jiao, L | 1 |
| Wu, Q | 2 |
| Zhao, Z | 2 |
| Song, J | 2 |
| Liu, T | 2 |
| Lv, Y | 1 |
| Lu, X | 1 |
| Ying, B | 2 |
| Yuliwulandari, R | 1 |
| Prayuni, K | 1 |
| Susilowati, RW | 1 |
| M Sofro, AS | 1 |
| Tokunaga, K | 1 |
| Shin, JG | 1 |
| Wang, Y | 2 |
| Xiang, X | 1 |
| Wu, SQ | 2 |
| Chen, G | 2 |
| Zhang, MM | 2 |
| Wang, MG | 1 |
| Wang, FJ | 1 |
| Sandford, AJ | 1 |
| He, JQ | 2 |
| Feng, M | 1 |
| Wu, JC | 3 |
| Ji, GY | 1 |
| Liu, QQ | 1 |
| Chan, SL | 1 |
| Chua, APG | 1 |
| Aminkeng, F | 1 |
| Chee, CBE | 1 |
| Jin, S | 1 |
| Loh, M | 1 |
| Gan, SH | 1 |
| Wang, YT | 1 |
| Brunham, LR | 1 |
| Khan, S | 1 |
| Mandal, RK | 1 |
| Elasbali, AM | 1 |
| Dar, SA | 1 |
| Jawed, A | 1 |
| Wahid, M | 1 |
| Mahto, H | 1 |
| Lohani, M | 1 |
| Mishra, BN | 1 |
| Akhter, N | 1 |
| Rabaan, AA | 1 |
| Haque, S | 1 |
| Hu, X | 1 |
| Peng, W | 1 |
| Chen, X | 1 |
| Ho, HT | 1 |
| Wang, TH | 1 |
| Hsiong, CH | 1 |
| Perng, WC | 1 |
| Wang, NC | 1 |
| Huang, TY | 1 |
| Jong, YJ | 1 |
| Lu, PL | 1 |
| Hu, OY | 1 |
| Gupta, VH | 1 |
| Amarapurkar, DN | 1 |
| Singh, M | 1 |
| Sasi, P | 1 |
| Joshi, JM | 1 |
| Baijal, R | 1 |
| Ramegowda, PH | 1 |
| Amarapurkar, AD | 1 |
| Joshi, K | 1 |
| Wangikar, PP | 1 |
| Verhagen, LM | 1 |
| Coenen, MJ | 1 |
| López, D | 1 |
| García, JF | 1 |
| de Waard, JH | 1 |
| Schijvenaars, MM | 1 |
| Hermans, PW | 1 |
| Aarnoutse, RE | 1 |
| Sheng, YJ | 1 |
| Wu, G | 1 |
| He, HY | 1 |
| Chen, W | 1 |
| Zou, YS | 1 |
| Li, Q | 1 |
| Zhong, L | 1 |
| Huang, YM | 1 |
| Deng, CL | 1 |
| Boelsterli, UA | 1 |
| Lee, KK | 1 |
| Ng, CS | 1 |
| Hasnat, A | 1 |
| Al Maruf, A | 1 |
| Ahmed, MU | 1 |
| Pirmohamed, M | 1 |
| Day, CP | 2 |
| Aithal, GP | 1 |
| Daly, AK | 2 |
| Guaoua, S | 2 |
| Ratbi, I | 2 |
| Laarabi, FZ | 1 |
| Elalaoui, SC | 1 |
| Jaouad, IC | 1 |
| Barkat, A | 1 |
| Sefiani, A | 2 |
| El Bouazzi, O | 1 |
| Hammi, S | 1 |
| Tebaa, A | 1 |
| Bourkadi, JE | 1 |
| Bencheikh, RS | 1 |
| Nalbandian, A | 1 |
| Yan, BS | 1 |
| Pichugin, A | 1 |
| Bronson, RT | 1 |
| Kramnik, I | 1 |
| Lee, SW | 1 |
| Chung, LS | 1 |
| Huang, HH | 1 |
| Chuang, TY | 1 |
| Liou, YH | 1 |
| Wu, LS | 1 |
| Liss, G | 1 |
| Rattan, S | 1 |
| Lewis, JH | 1 |
| Stirnimann, G | 1 |
| Kessebohm, K | 1 |
| Lauterburg, B | 1 |
| Ben Mahmoud, L | 1 |
| Ghozzi, H | 1 |
| Kamoun, A | 1 |
| Hakim, A | 1 |
| Hachicha, H | 1 |
| Hammami, S | 1 |
| Sahnoun, Z | 1 |
| Zalila, N | 1 |
| Makni, H | 1 |
| Zeghal, K | 1 |
| Teixeira, RL | 1 |
| Morato, RG | 1 |
| Cabello, PH | 1 |
| Muniz, LM | 1 |
| Moreira, Ada S | 1 |
| Kritski, AL | 1 |
| Mello, FC | 1 |
| Suffys, PN | 1 |
| Miranda, AB | 1 |
| Santos, AR | 1 |
| Leiro-Fernandez, V | 1 |
| Valverde, D | 2 |
| Vázquez-Gallardo, R | 1 |
| Botana-Rial, M | 1 |
| Constenla, L | 2 |
| Agúndez, JA | 1 |
| Fernández-Villar, A | 2 |
| Nanashima, K | 1 |
| Mawatari, T | 1 |
| Tahara, N | 1 |
| Higuchi, N | 1 |
| Nakaura, A | 1 |
| Inamine, T | 1 |
| Kondo, S | 1 |
| Yanagihara, K | 1 |
| Fukushima, K | 1 |
| Suyama, N | 1 |
| Kohno, S | 1 |
| Tsukamoto, K | 1 |
| Urban, TJ | 1 |
| Goldstein, DB | 1 |
| Watkins, PB | 1 |
| Azuma, J | 1 |
| Ohno, M | 1 |
| Kubota, R | 1 |
| Yokota, S | 1 |
| Nagai, T | 1 |
| Tsuyuguchi, K | 1 |
| Okuda, Y | 1 |
| Takashima, T | 1 |
| Kamimura, S | 1 |
| Fujio, Y | 1 |
| Kawase, I | 1 |
| Santos, NP | 1 |
| Callegari-Jacques, SM | 1 |
| Ribeiro Dos Santos, AK | 1 |
| Silva, CA | 1 |
| Vallinoto, AC | 1 |
| Fernandes, DC | 1 |
| de Carvalho, DC | 1 |
| Santos, SE | 1 |
| Hutz, MH | 1 |
| Huang, YS | 2 |
| Chern, HD | 2 |
| Su, WJ | 2 |
| Chang, SC | 1 |
| Chiang, CH | 1 |
| Chang, FY | 2 |
| Lee, SD | 2 |
| Leiro, V | 1 |
| Vázquez, R | 1 |
| Piñeiro, L | 1 |
| González-Quintela, A | 1 |
| Sinués, B | 1 |
| Rueda, P | 1 |
| Benítez, J | 1 |
| Saenz, MA | 1 |
| Bernal, ML | 1 |
| Lanuza, J | 1 |
| Alda, O | 1 |
| Tres, A | 1 |
| Bartolome, M | 1 |
| Ishizu, S | 1 |
| Hashida, C | 1 |
| Hanaoka, T | 1 |
| Maeda, K | 1 |
| Ohishi, Y | 1 |
| Lai, SL | 1 |
| Yang, SY | 1 |
| Brown, SL | 1 |
| Albuquerque, TAF | 1 |
| Drummond do Val, L | 1 |
| Doherty, A | 1 |
| de Magalhães, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00298870] | Phase 4 | 172 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for isoniazid and Genetic Predisposition
| Article | Year |
|---|---|
Pharmacogenetic association between
Topics: Alleles; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injur | 2019 |
The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 CYP2E1; Gene Frequency; Genet | 2014 |
Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.
Topics: Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injur | 2014 |
Predicting and preventing acute drug-induced liver injury: what's new in 2010?
Topics: Acetaminophen; Adult; Aged; Aging; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combinati | 2010 |
Liver injury caused by drugs: an update.
Topics: Acetaminophen; Adaptive Immunity; Analgesics, Non-Narcotic; Antitubercular Agents; Apoptosis; Chemic | 2010 |
Genetic association studies in drug-induced liver injury.
Topics: Antitubercular Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Drug-Related Si | 2012 |
From humans to hydra: patterns of cancer across the tree of life.
Topics: Animals; Biological Evolution; Genetic Predisposition to Disease; Humans; Hydra; Neoplasms; Species | 2018 |
2 trials available for isoniazid and Genetic Predisposition
| Article | Year |
|---|---|
Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Topics: Adult; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Drug Therapy, Co | 2017 |
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Topics: Adult; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Asian People; Chemical and Dru | 2013 |
25 other studies available for isoniazid and Genetic Predisposition
| Article | Year |
|---|---|
Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Asian People; ATP-Binding Cassette Transporters; | 2020 |
NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltr | 2019 |
Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Topics: Adult; Alleles; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Cytochr | 2017 |
Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Biomarkers, Pharmacological; Case-Control Stud | 2017 |
Genetic polymorphisms of long noncoding RNA RP11-37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China.
Topics: Adult; Anemia; Antitubercular Agents; Asian People; Case-Control Studies; China; Female; Genetic Pre | 2019 |
The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.
Topics: Adult; Aged; Alleles; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induce | 2013 |
Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; | 2013 |
Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis.
Topics: Adolescent; Arylamine N-Acetyltransferase; Child; Child, Preschool; Female; Genetic Predisposition t | 2014 |
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Asia; Case-Control Studies; Chemical an | 2014 |
Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; Cytoch | 2014 |
NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltransferase; Ca | 2016 |
Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control.
Topics: Animals; Antitubercular Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chronic D | 2009 |
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and D | 2010 |
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; | 2012 |
Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Topics: Acetylation; Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Brazil; Case-Control Studi | 2011 |
N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Case-Control Studies; Chemical and Drug | 2011 |
Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Basic-Leucine Zipper Transcription Factors; C | 2012 |
Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?
Topics: Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; Floxacillin; Genetic Predispo | 2012 |
N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
Topics: Acetylation; Adult; Alanine Transaminase; Antitubercular Agents; Arylamine N-Acetyltransferase; Biom | 2013 |
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Alleles; Antitubercular Agents; Chemical and Drug Induc | 2003 |
Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Case-Control Studie | 2008 |
Thioether excretion, urinary mutagenicity, and metabolic phenotype in smokers.
Topics: Acetylation; Adult; Biomarkers; Creatinine; Debrisoquin; Female; Genetic Predisposition to Disease; | 1994 |
N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Arylamine N-Acetyltransferase; Asian People | 1995 |
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Topics: Acetylation; Aged; Aging; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug In | 2002 |
Differential susceptibility: implications for epidemiology, risk assessment, and public policy.
Topics: Acetylation; Animals; Benzidines; Carcinogens, Environmental; Genetic Predisposition to Disease; Gen | 1988 |